Author

Malika Souquieres

Observed name: Malika Souquières

Institution: Priothera SAS (France)

Observed institutions: Novartis (Switzerland), Novartis Institutes for BioMedical Research, Priothera SAS (France)

OpenAlex ID: A5010485236

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

2022 · Diane M. Thiboutot, Noah Craft, et al. · Journal of Dermatological Treatment · 13

MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

2024 · Gabriela Sanchez-Petitto, Maria Calbacho, et al. · Blood · 2

P1282: Mocravimod Improves Overall Survival in Aml Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

2023 · Michael Medinger, Jakob Passweg, et al. · HemaSphere

A Phase IIb placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

2023 · Eduardo Olavarria, Malika Souquieres, et al. · http://isrctn.com/

MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant

2022 · Marcos de Lima, Florent Malard, et al. · Blood

Works count: 6

Citation count: 15

H-index: 2

I10-index: 1